How does 0JDI's PS Ratio compare to its peers?

0JDI is expensive based on its Price-To-Sales Ratio (6.7x) compared to the peer average (5.6x).

How does 0JDI's PS Ratio compare vs other companies in the GB Biotechs Industry?

0JDI is good value based on its Price-To-Sales Ratio (6.7x) compared to the European Biotechs industry average (7.9x).

What is 0JDI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0JDI is expensive based on its Price-To-Sales Ratio (6.7x) compared to the estimated Fair Price-To-Sales Ratio (4x).

What is the Fair Price of 0JDI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0JDI ($34.72) is trading above our estimate of [[fair value]] ($4.46)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Ionis Pharmaceuticals (LSE:0JDI) - Stock Price, News & Analysis

0JDI Stock Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. More details

0JDI fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 21.86% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Ionis Pharmaceuticals, Inc. Competitors

Genus

LSE:GNS

UK£1.1b

Oxford Biomedica

LSE:OXB

UK£442.5m

Bioventix

AIM:BVXP

UK£195.7m

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

Price History & Performance

Summary of all time highs, changes and price drops for Ionis Pharmaceuticals
Historical stock prices
Current Share Price	US$34.72
52 Week High	US$53.95
52 Week Low	US$33.55
Beta	0.39
11 Month Change	-11.14%
3 Month Change	-25.96%
1 Year Change	-30.53%
33 Year Change	18.50%
5 Year Change	-40.53%
Change since IPO	-34.43%

Recent updates

Shareholder Returns

	0JDI	GB Biotechs	GB Market
7D	-1.2%	0.3%	2.2%
1Y	-30.5%	-18.3%	8.0%

Return vs Industry: 0JDI underperformed the UK Biotechs industry which returned -18.3% over the past year.

Return vs Market: 0JDI underperformed the UK Market which returned 8% over the past year.

Price Volatility

Is 0JDI's price volatile compared to industry and market?
0JDI volatility
0JDI Average Weekly Movement	5.5%
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0JDI has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0JDI's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1989	927	Brett Monia	www.ionispharma.com

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.

Ionis Pharmaceuticals, Inc. Fundamentals Summary

How do Ionis Pharmaceuticals's earnings and revenue compare to its market cap?
0JDI fundamental statistics
Market cap	US$5.37b
Earnings (TTM)	-US$358.81m
Revenue (TTM)	US$803.07m

6.7x

P/S Ratio

-15.0x

P/E Ratio

Is 0JDI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JDI income statement (TTM)
Revenue	US$803.07m
Cost of Revenue	US$917.98m
Gross Profit	-US$114.91m
Other Expenses	US$243.90m
Earnings	-US$358.81m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.27
Gross Margin	-14.31%
Net Profit Margin	-44.68%
Debt/Equity Ratio	275.7%

How did 0JDI perform over the long term?

See historical performance and comparison

0JDI Stock Overview

Rewards

Risk Analysis

Ionis Pharmaceuticals, Inc. Competitors

LSE:GNS

UK£1.1b

LSE:OXB

UK£442.5m

AIM:BVXP

UK£195.7m

LSE:HIK

UK£4.3b

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: US$0.94 loss per share (vs US$1.03 loss in 3Q 2023)

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $500.25 million.

Recent updates

Third quarter 2024 earnings released: US$0.94 loss per share (vs US$1.03 loss in 3Q 2023)

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $500.25 million.

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.45 loss per share (vs US$0.60 loss in 2Q 2023)

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces Positive Detailed Results from the HALOS Study of ION582 in People with Angelman Syndrome

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

First quarter 2024 earnings released: US$0.98 loss per share (vs US$0.87 loss in 1Q 2023)

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$2.56 loss per share (vs US$1.90 loss in FY 2022)

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$1.03 loss per share (vs US$0.33 loss in 3Q 2022)

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.74 loss in 2Q 2022)

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

First quarter 2023 earnings released: US$0.87 loss per share (vs US$0.46 loss in 1Q 2022)

Full year 2022 earnings released: US$1.90 loss per share (vs US$0.20 loss in FY 2021)

Founder recently sold US$1.0m worth of stock

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Insufficient new directors

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.58 loss in 3Q 2021)

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Second quarter 2022 earnings released: US$0.74 loss per share (vs US$0.57 loss in 2Q 2021)

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2B Clinical Study of Fesomersen

Ionis Pharmaceuticals, Inc. Announces FDA Accepts New Drug Application and Grants Priority Review of Tofersen for A Rare, Genetic Form of ALS

Ionis Announces Enrollment Completion of Phase 3 Lp(a) HORIZON Cardiovascular Outcomes Study of Pelacarsen